Mizuho raised the firm’s price target on Amylyx (AMLX) to $19 from $18 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx price target raised to $28 from $20 at H.C. Wainwright
- Buy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support Upside
- Amylyx Advances AMX0318 as New Rare-Disease Candidate
- Amylyx selects AMX0318 as development candidate for PBH
- Amylyx price target lowered to $15 from $16 at BofA